Advertisement: TTP Killer 50
2 July, 2018 - 15:33 By News Desk

Atlantic Healthcare

An emerging transatlantic pharmaceutical group with an existing focus on gastrointestinal disorders. The Group intends to market its products directly in Europe and the US, and partner in other markets including Canada and Japan. 

The Group's lead product, alicaforsen, is progressing through Phase 3 clinical development in pouchitis, a form of inflammatory bowel disease (IBD), and has potential applications in multiple GI and IBD indications.

atlantichc.com

Newsletter Subscription

Stay informed of the latest news and features